Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK

Abstract

The purpose of this paper is to identify the treatment patterns and corresponding costs of healthcare resource use associated with palliative care for different types of advanced cancer patients, from the time they started strong opioid treatment until death. This was a modelling study performed from the perspective of the UK's National Health Service (NHS). A data set was created comprising 547 patients in the DIN-Link database who had a Read code for malignant neoplasms with a specific tumour-type diagnosis and who received their first strong opioid between 1 January 1998 and 30 September 2000 and died during that period. Palliative care-related resource utilization data were obtained from the DIN-Link database. Unit costs at 2000/2001 prices were applied to the resource use estimates to determine the mean cost of palliative care from the start of treatment until death. There were significant differences in age between patients with different cancer types and in patients' survival from diagnosis, time to the start of palliative care and duration of palliative care. The mean duration from cancer diagnosis to the start of strong opioid treatment ranged from 0.7 to 5.4 years in patients with lung and breast cancer respectively. Moreover, the length of palliative care ranged from 180 to 372 days in patients with these cancer types respectively. There were also statistically significant differences in resource use between patients with different cancer types, but this reflected, in part, the varying durations of palliative care. Nevertheless, there were also differences in the monthly number of primary care visits reflecting the different number of monthly prescriptions. There was no apparent relationship between the length and corresponding cost of palliative care which ranged from 1816 pounds sterling for colon cancer to 4789 pounds sterling for ovarian cancer. Additionally, on average, only a third of all patients also received 4-hourly morphine as part of their initial strong opioid treatment. The total cost of palliative care varied between cancer type and reflects, at least in part, the distinct clinical features associated with different tumours and the varying lengths of survival following the start of strong opioid treatment. Nevertheless, no apparent relationship was found between length of palliative care and corresponding costs. This analysis provides data on palliative care resource use for a variety of cancers and could provide useful input when planning local healthcare strategies and building service commissioning models.

Cost of care for colorectal cancer in Ireland: a health care payer perspective

“…Cost of radiotherapy was based on a study by Ploquin and Dunscombe [43] and confirmed by local expert radiotherapy clinical opinion. The cost of best supportive care was obtained from a study conducted by Guest et al [44].…”

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation

“…The palliative cost associated with ovarian cancer was estimated by Guest et al 112 to be £4789 (at 2000-1 prices) for an average time period of 399 days. This cost predominantly consisted of hospitalisation costs (71% of costs), updating the estimate of palliative care for patients with ovarian cancer from Guest et al 112 to current prices using the Hospital & Community Health Services index results in a cost of £6963, equating to £531 per month. This cost is applied monthly to all PRR patients following entry into the PD health state, and all platinum-sensitive patients following 6 months of residence in the PD health state.…”

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

“…Resource use estimates were based on Study 19 [19], previous appraisals [28], clinical guidelines [14], literature [29][30][31] and assumptions. Unit costs were derived from NHS Reference Costs 2013-14 [32], the Personal Social Services Research Unit (PSSRU) [33], the NHS Commercial Medicines Unit (CMU) [34] and the BNF [12].…”